| pubmed-article:11266417 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11266417 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:11266417 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11266417 | lifeskim:mentions | umls-concept:C0052796 | lld:lifeskim |
| pubmed-article:11266417 | lifeskim:mentions | umls-concept:C0054066 | lld:lifeskim |
| pubmed-article:11266417 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:11266417 | lifeskim:mentions | umls-concept:C0238990 | lld:lifeskim |
| pubmed-article:11266417 | lifeskim:mentions | umls-concept:C1442459 | lld:lifeskim |
| pubmed-article:11266417 | lifeskim:mentions | umls-concept:C1547061 | lld:lifeskim |
| pubmed-article:11266417 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11266417 | pubmed:dateCreated | 2001-3-27 | lld:pubmed |
| pubmed-article:11266417 | pubmed:abstractText | To compare the efficacy, safety and tolerability of a 3 day course of azithromycin with a 10 day course of co-amoxiclav in the treatment of children with acute lower respiratory tract infection (LRTI), 118 patients with community-acquired LRTI were included in a multicentre randomized double-blind, double-dummy study. The diagnosis of LRTI was based on the presence of respiratory signs and symptoms in combination with consolidation on a chest radiograph or clinical evidence of LRTI. Patients received oral azithromycin suspension (10 mg/kg/24 h) or placebo in one dose for 3 days and co-amoxiclav (45/11.25 mg/kg/24 h) or placebo in three doses for 10 days. Of 110 eligible patients, 56 and 54 patients, respectively, were treated with azithromycin or co-amoxiclav. The percentage of patients cured or clinically improved at days 10-13 (primary endpoint) was 91% for azithromycin and 87% for co-amoxiclav. This difference of 4% (90% confidence interval: -6%, +14%) was not statistically significant (P= 0.55). Significantly (P = 0.01) more related adverse events were found in the co-amoxiclav group. This was largely due to a higher percentage (43% versus 19%) of gastrointestinal complaints. A 3 day course of azithromycin (three doses) is as effective in the treatment of LRTI in children as a 10 day course of co-amoxiclav (30 doses). The azithromycin group had fewer adverse events. We conclude that azithromycin is an effective, safe and well-tolerated drug in the treatment of children with LRTI. An additional advantage is the easy administration and short duration of therapy. | lld:pubmed |
| pubmed-article:11266417 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11266417 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11266417 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11266417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11266417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11266417 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11266417 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11266417 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:11266417 | pubmed:issn | 0305-7453 | lld:pubmed |
| pubmed-article:11266417 | pubmed:author | pubmed-author:HopW CWC | lld:pubmed |
| pubmed-article:11266417 | pubmed:author | pubmed-author:RobbenS GSG | lld:pubmed |
| pubmed-article:11266417 | pubmed:author | pubmed-author:de GrootRR | lld:pubmed |
| pubmed-article:11266417 | pubmed:author | pubmed-author:KouwenbergJ... | lld:pubmed |
| pubmed-article:11266417 | pubmed:author | pubmed-author:FerwerdaAA | lld:pubmed |
| pubmed-article:11266417 | pubmed:author | pubmed-author:Tjon Pian... | lld:pubmed |
| pubmed-article:11266417 | pubmed:author | pubmed-author:MollH AHA | lld:pubmed |
| pubmed-article:11266417 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11266417 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:11266417 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11266417 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11266417 | pubmed:pagination | 441-6 | lld:pubmed |
| pubmed-article:11266417 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:meshHeading | pubmed-meshheading:11266417... | lld:pubmed |
| pubmed-article:11266417 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11266417 | pubmed:articleTitle | Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. | lld:pubmed |
| pubmed-article:11266417 | pubmed:affiliation | Department of Paediatrics, Sophia Children's Hospital/University Hospital, Rotterdam, The Netherlands. | lld:pubmed |
| pubmed-article:11266417 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11266417 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11266417 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11266417 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11266417 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:11266417 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11266417 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11266417 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11266417 | lld:pubmed |
